TAMPA, Florida, May 20, 2013 /PRNewswire/ --
Elsevier will provide Apex with essential drug information in a streamlined database solution
Elsevier, a world-leading provider of scientific, medical and technical information products and services, today announced an agreement with Apex Affinity, provider of innovative prescription discount programs for uninsured and underinsured families nationwide. Apex has selected Elsevier's Gold Standard Drug Database for providing current and accurate drug content to enhance its member products, including a new consumer drug reference portal.
Apex leverages the purchasing power of millions of consumers to negotiate deep discounts on brand-name and generic prescriptions at nearly all major big box stores, drug store chains and independent neighborhood pharmacies. Apex will use Elsevier's Gold Standard Drug Database to enable members to compare drug pricing, look-up accurate dosage information, and learn about alternative therapies and what a medication is used for and what it does.
"With the Gold Standard Drug Database, we can provide our members with the most up-to-date drug information in an easy to use format," said Scott Paul, Apex's Chief Executive Officer. "It will help our members make informed decisions about their medications and their health."
The Gold Standard Drug Database content is updated daily and has a peer-reviewed editorial process in place to ensure the highest accuracy of drug product information, drug pricing and patient education information. Apex will benefit from the database's modern technical architecture and flexible implementation, which distinguishes Gold Standard Drug Database from other drug databases.
"With the implementation of our Gold Standard Drug Database, Apex will have the confidence that their value-added consumer reference products contain superior drug information that allows their members to swiftly and effortlessly research their medications," said Trygve Anderson, R.Ph.
Vice President of Product Management, Elsevier's Gold Standard.
For more information about Elsevier's Gold Standard, please visit http://www.goldstandard.com.
# # #
About Apex Affinity
Apex Affinity provides innovative services that help organizations reach new customers, increase satisfaction and loyalty, and create new revenue streams. From traditional retail discount cards to the latest e-marketing technologies, Apex enables affinity groups to engage their members, offer high-value services, and grow. For more information, visit http://www.apexaffinity.com.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Director, Corporate Relations, Elsevier